Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
LPLipocine Inc. logo

Lipocine Inc. (LPCN)

NASDAQ Capital Market · Currency in USD
$1.44 ▼ -0.02 (-1.37%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.44 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:14 PM ET

Summary

Previous Close
$1.46
Open
$1.45
Day's Range
$1.41 – $1.46
52 Week Range
$1.40 – $12.37
Volume
217,758
Avg. Volume
54,210
Market Cap
$11.87M
Beta (5Y Monthly)
0.47
PE Ratio (TTM)
--
EPS (TTM)
-$1.44
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$4.00

Profile: Lipocine Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
14
CEO
Mahesh V. Patel

Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.39 · Revenue est. $159.50K
DateEst.Actual
Aug 4, 2026-$0.40-$0.32Beat
May 7, 2026-$0.51-$0.54Miss
Mar 9, 2026-$0.60-$0.34Beat
Nov 6, 2025-$0.56-$0.59Miss
Aug 5, 2025-$0.41-$0.41Beat
May 8, 2025-$0.35-$0.35Beat

Analyst view

Consensus price target
$4.00 ▲ +177.8%
Range $4.00 – $4.00
Rating: Buy
Buy 78% · Hold 22% · Sell -0%

Get free alerts on LPCN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.